MarketPulse

retatrutide

3 articles
BenzingaBenzinga··Vandana Singh

Eli Lilly Phases Out Select European Insulin Products by 2027

Eli Lilly discontinuing select insulin products across EU/EEA by Q2 2027 due to commercial factors. Company's experimental retatrutide shows strong diabetes and weight-loss results.
LLYweight lossEurope
BenzingaBenzinga··Vandana Singh

Eli Lilly's Diabetes Drug Delivers 17% Weight Loss, But Analysts Question Valuation

Eli Lilly's retatrutide shows strong weight loss results in trials, but HSBC downgrades stock citing overvaluation concerns.
LLYclinical trialweight loss
BenzingaBenzinga··Vandana Singh

Novo Nordisk's China Obesity Treatment Achieves 19.7% Weight Loss in Phase 2 Trial

Novo Nordisk's obesity drug UBT251 achieved 19.7% weight loss in Phase 2 trials for Chinese patients, offsetting recent setbacks from a failed competitor drug trial.
LLYNVOclinical trialweight loss